skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 
The past 18 months have been momentous for Avacta (LSE:AVCT), the AIM-listed developer of diagnostics and cancer therapies based on its proprietary Affimer and pre|CISION platforms. Investors with shares in the company in March 2020 saw the value of their stock surge 800% in six weeks, after the World Health Organisation declared Covid-19 virus a pandemic on 12 March. Avacta was able to secure first-mover advantage with some key diagnostic tools to fight the virus, while continuing to develop its cancer therapies. A note from in-house broker Stifel in April stated that 2021 would be a ‘breakthrough year’, but it is difficult to see how last year’s performance can be repeated. There is little sign yet of that happening. In fact, after a strong 2Q when shares reached 275p, the share price has been on an unstoppable slide, losing more than half its value, despite some positive news flow, rumours about a government contract and claims of an “ongoing dialogue” with the Department of Health.

Important ISO 13485 certification for Avacta

Expectations that Avacta might secure the CE mark authorisation of the test in May, ahead of the commercial roll-out in Europe later in the year, were disappointed. Progress has been slow, but last month Avacta was granted the ISO 13485 certification for the manufacture and distribution of its Affimer reagents for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.


The rest of this page is for members only. Please log in below or visit the registration page for Armchair Trader+ to see the benefits of becoming a member.

Log In or Sign Up to Armchair Trader+

Already a member? Log in here:

Not a member yet? Sign up for your free trial or check out the benefits of membership.

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader+ for further details on the benefits of becoming a member.

Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

James Norris

James Norris

James is a highly experienced writer and editor, gained from more than 20 years in the financial services industry, in particular wealth management and asset management.

He initially worked as a financial journalist for a number of leading media brands, including the FT Group, Financial News, Euromoney and Incisive Media, covering most aspects of the asset management industry. More recently, James switched to work as an in-house content specialist for fund management and wealth management groups, including JP Morgan Asset Management, Quilter Cheviot Investment Management, AXA Investment Managers and Invesco Perpetual.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.


Subscribe for more stories like this, 8am weekdays - for free!

Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top